Filing search / Olema Pharmaceuticals, Inc. / "Strategy"

8-K

EX-99.1

OLMA Olema Pharmaceuticals, Inc.

27 Sep 24

Regulation FD Disclosure

7:00am

candidates, strategy, market size and opportunity, clinical trial designs, regulatory matters, including the timing and likelihood of success of obtaining … of rapamycin inhibitor 1st line combo with CDK4/6i ribociclib In Planning In collaboration with In collaboration with In collaboration with Strategy driven

8-K

EX-99.2

OLMA Olema Pharmaceuticals, Inc.

15 May 24

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

7:06am

candidates, strategy, regulatory matters, including the timing and likelihood of success of obtaining drug approvals, the timelines for potential

8-K

EX-99.1

i59zhhs

8 Jan 24

Olema Oncology JP Morgan Conference January 2024

9:07am

424B5

ijy ehzp6wk6b5rjs

5 Jan 24

Prospectus supplement for primary offering

5:25pm

8-K

EX-99.1

ijiftby23c04shis

6 Dec 23

Regulation FD Disclosure

7:48am

8-K

EX-99.2

lgljzx7

23 Oct 23

Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

7:45am